Is Johnson & Johnson (JNJ) a risky stock?
As of July 21, 2026, Clavix grades Johnson & Johnson (JNJ) A for risk, a composite score of 91 out of 100 on an A+ to F scale, which puts JNJ in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind JNJ's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how JNJ scores on each, as of July 21, 2026.
What's moving JNJ's risk right now
Company-specific signals Clavix flags behind JNJ's current grade, drawn from recent news and filings as of July 21, 2026.
Hillsdale Investment Management cut its JNJ holdings by 31.1% in the first quarter, according to its 13F SEC filing. A separate JNJ 8-K material event filing was also reported with no added detail.
Freedom Capital raised its rating on JNJ to Strong-Buy, citing confidence in the company's near-term results. The upgrade could draw in more institutional buyers and offer short-term price support.
Guggenheim kept a Buy rating on JNJ and set a $270 price target, signaling confidence in the company's valuation and outlook. The target implies upside from current trading levels.
What a A grade means
On the Clavix A+ to F scale, JNJ's composite of 91 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell JNJ or any security. Grades are risk indicators, not predictions of return. Data may be delayed.